Adjuvant activity of incomplete Freund's adjuvant

Advanced Drug Delivery Reviews

Volumn 32, Issue 3, 1998, Pages 173-186

  Chang, Jennie C C ^a   Diveley, Jocelyn P ^a   Savary, Jay R ^a   Jensen, Fred C ^a  

^a Orchestra Therapeutics Inc   (United States)

Author keywords

Antibody; Autoimmunity; Cell mediated immunity responses; HIV 1; Water in oil emulsion

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; EMULSIONS; TOXICITY; VACCINES;

AUTOIMMUNITY; INCOMPLETE FREUND'S ADJUVANT (IFA); WATER IN OIL EMULSIONS;

CONTROLLED DRUG DELIVERY;

ALUMINUM HYDROXIDE; ANTIGEN P24; CYTOKINE; FREUND ADJUVANT; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12; PHOSPHORYL LIPID A; QS 21; QUIL A; SAPONIN; T LYMPHOCYTE RECEPTOR; WATER OIL CREAM;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CLINICAL TRIAL; EMULSION; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RABBIT; REVIEW; RHEUMATOID ARTHRITIS; VACCINE PRODUCTION;

EID: 0032490613     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00009-X     Document Type: Review

References (47)

1. Freund J., Casals J., Hosmer E.P. Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Proc. Soc. Exp. Biol. 37:1937;509-513.
2. Freund J. Some aspects of active immunization. Annu. Rev. Microbiol. 1:1947;291-308.
3. Freund J. The effect of paraffin oil and mycobacteria on antibody formation and sensitization: a review. Am. J. Clin. Pathol. 21:1951;645-656.
4. D.E.S. Stewart-Tull, Freud-type Mineral Oil Adjuvant Emulsions, in: D.E.S. Stewart-Tull (Ed.), The Theory and Practical Application of Adjuvants, Joh Wiley and Sons, New York, 1995, pp. 1-20.
5. Salk J.E., Contakos A.B., Laurent A.M.et al. Use of adjuvants in studies on influenza immunization: III. Degree of persistence of antibody in human subjects two years after vaccination. J. Am. Med. Assoc. 151:1953;1169-1175.
6. Salk J.E., Laurent A.M. Use of adjuvants in studies on immunization: measurements in monkeys of dimensions of antigenicity of virus-mineral oil emulsions. J. Exp. Med. 95:1952;429-647.
7. Salk J.E., Laurent A.M., Bailey M.L. Direction of research on vaccination against influenza: new studies with immunologic adjuvants. Am. J. Pub. Health. 41:1951;669-677.
8. Salk J.E., Bailey M.L., Laurent A.M. Use of adjuvants in studies on immunization: II. Increased antibody formation in human subjects inoculated with influenza virus vaccine in water-in-oil emulsion. Am. J. Hygiene. 55:1952;439-456.
9. Progress Report to the Medical Research Council by Committee on Clinical Trials of Influenza Vaccine. Clinical trials of influenza vaccine. Br. Med. J. ii (1953) 1173-1177.
10. Medical Research Council Committee on Clinical Trials of Influenza Vaccine. Br. Med. J. ii (1955) 1229-1232.
11. Davenport F.M., Hennessy A.V., Houser H.B., Cryns W.F. Evaluation of adjuvant influenza virus vaccine tested against influenza B, 1954-1955. Am. J. Hygiene. 63:1956;304-313.
12. Davenport F.M., Hennessy A.V. Serologic recapitulation of past experiences with influenza A: antibody response to monovalent vaccine. J. Exp. Med. 104:1956;85-97.
13. Bell J.A., Philip R.N., Davis D.J.et al. Epidemiologic studies on influenza in familial and general population groups, 1951-1956: IV. Vaccine reactions. Am. J. Hygiene. 73:1961;148-163.
14. Davenport F.M. Seventeen years experience with mineral oil adjuvant influenza virus vaccines. Ann. Allergy. 26:1968;288-292.
15. MacLennan R., Schofield F.D., Pittmann M. Immunization against neonatal tetanus in New Guinea: antitoxin response of pregnant women to adjuvant and plain toxoids. Bull. World Health Org. 32:1965;683-697.
16. Ogonuki H., Hashizume S.O., Takashaski B. Preparation and laboratory tests of oil adjuvant cholera vaccine. Bull. World Health Org. 37:1967;729-736.
17. Triozzi P.L., Gochnour D., Martin E.W., Aldrich W., Powell J., Kim J.A., Young D.C., Lombardi J. Clinical and immunologic effects of a synthetic β-human chorionic gonadotropin vaccine. Int. J. Oncol. 5:1994;1447-1453.
18. Gibbs C.J., Peters R., Gravell M., Johnson B.K., Jensen F.C., Carlo D.J., Salk J. Observations after human immunodeficiency Virus immunization and challenge of human immunodeficiency virus seropositive and chimpanzees. Proc. Natl. Acad. Sci. USA. 88:1991;3348-3352.
19. Salk J. Prospects for the control of AIDS by immunizing seropositive individuals. Nature. 327:1987;473-476.
20. Levine A.M., Groshen S., Allen J., Munson K.M., Carlo D.J., Daigle A.E., Ferre F., Jensen F.C., Richieri S.P., Trauger R.J., Parker J.W., Salk P.L., Salk J. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 immunogen: long-term follow-up. J. AIDS Human Retrovirol. 11:1996;351-364.
21. Trauger R.J., Ferre F., Daigle A.E., Jensen F.C., Moss R.B., Mueller S.H., Richieri S.P., Slade H.B., Carlo D.J. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J. Infect. Dis. 169:1994;1256-1264.
22. Moss R.B., Trauger R.J., Giermakowska W.K., Turner J.L., Wallace M.R., Jensen F.C., Richieri S.P., Ferre F., Daigle A.E., Duffy P.C., Rheofan G., Carlo D.J. Effect of immunization with an gp 120-depleted HIV-1 immunogen on ß-chemokine and cytokine production in subjects with HIV-1 infection. J. AIDS Human Retrovirol. 14:1997;343-350.
23. Moreland L.W., Heck L.W. Jr., Koopman W.J., Saway P.A., Adamson T.C., Fronek Z., O'Connor R.D., Morgan E.E., Diveley J.P., Richieri S.P., Carlo D.J., Brostoff S.W. Vβ17 T-cell receptor peptide vaccination in rheumatoid arthritis: results of phase I dose escalation study. J. Rheumatol. 23:1996;1353-1362.
24. Wilson D.B., Golding A.B., Smith R.A., Dafashy T., Nelson J., Smith L., Carlo D.J., Brostoff S.W., Gold D.P. Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations. J. Neuroimmunol. 76:1997;15-28.
25. Gold D.P., Smith R.A., Golding A.B., Morgan E.E., Dagashy T., Nelson J., Smith L., Diveley J., Laxer J., Richieri S.P., Carlo D.J., Brostoff S.E., Wilson D.B. Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRVβ6 CDR2 peptide. J. Neuroimmunol. 76:1997;29-38.
26. Mosmann T.R., Coffman R.L. TH1 and Th2 cells: Differential patterns of lymphokine secretion lead to different functional properties. Ann. Rev. Immunol. 7:1989;145-173.
27. Wierenga E.A., Snock M., Jansen H.M., Bos J.D., van Lier R.A., Kapsenberg M.L. Human atopen-specific types 1 and 2 T helper cell clones. J. Immunol. 147:1991;2942-2949.
28. Parronchi P., Macchia D., Piccinni M.P., Biswas P., Simonelli C., Maggi E., Ricci M., Ansari A.A., Romagnani S. Allergin-and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production. Proc. Natl. Acad. Sci. USA. 88:1991;4538-4542.
29. Mazzi E., Parronchi P., Manetti R., Simonelli C., Piccinni M.P., Rugiu F.S., de Carli M., Romagnari S. Reciprocal regulatory effects of IFNγ and IL-4 on the in vitro development of human TH1 and TH2 clones. J. Immunol. 148:1992;2142-2147.
30. Abehsira-Amar O., Gilbert M., Joliy M., Theze J., Jankovic D. IL-4 plays a dominant role in the differential development of Th0 into Th1 and Th2 cells. J. Immunol. 148:1992;3820-3829.
31. Chatelain R., Varkila K., Coffman R.L. IL-4 induces a TH2 response in Leishmania major-infected mice. J. Immunol. 148:1992;1182-1187.
32. Bretscher P.A., Wei G., Menon J.N., Bielefeldt-Ohmann H. Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science. 257:1992;539-542.
33. + T-cells defined by their differential expression of variants of the CD45 antigen: development relationships and in vitro and in vivo functions. Curr. Top. Microbiol. Immunol. 159:1990;79-96.
34. + T-cells. Eur. J. Immunol. 21:1991;1187-1194.
35. A.J. McKnight, A.N. Barclay, D.W. Mason, Analysis of the lymphokine repertoire of rat T-cell subpopulations, in: S. Romagnani and A.K. Abbas (Eds.), Cytokines: Basic Principles and Clinical Applications. Raven Press, Ltd., New York, 1990, pp. 151-155.
36. Audibert F.M., Lise L.D. Adjuvants: current status, clinical prospectives and future prospects. Immunology Today. 14:1993;281-284.
37. Fernando G.J.P., Stenzel D.J., Tindle R.W., Merza M.S., Morein B., Frazer J.H. Peptide polymerization facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production. Vaccine. 13:1995;1460-1467.
38. Cox J.C., Coulter A.R. Adjuvants-a classification and review of their modes of action. Vaccine. 15:1997;248-256.
39. + cytotoxic T-cells by immunization with purified HIV-1 envelope protein in ISCOM. Nature. 344:1990;873-875.
40. Barr I.G., Mitchell G.F. ISCOMs (immunostimulating complexes): The first decade. Immunol. Cell. Biol. 74:1996;8-25.
41. Harding C.V., Collins D.S., Kanagawa O., Unanue R.R. Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. J. Immunol. 147:1991;2860-2863.
42. + T-cells and induces synthesis of IL-3 and IFN-gamma but not IL-4 or IL-6. Int. Immunol. 4:1992;475-485.
43. Afonso L.C., Scharton T.M., Viertra L.Q., Wysocka M., Trinchieri G., Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science. 263:1994;235-237.
44. Germann T., Szeliga J., Hess H., Storkel S., Podlaski F.J., Gately M.K., Schmitt E., Rude E. Administration of interleukin 12 in combination with type 11 collagen induces severe arthritis in DBA/1 mice. Proc. Natl. Acad. Sci. USA. 92:1995;4823-4827.
45. Kensil C.R., Patel U., Lennick M., Marciani D. Separation and characterization of saponins with adjuvant activity form Quillaja saponaria molina cortex. J. Immunol. 146:1991;431-437.
46. Newman M.J., Wu J.Y., Cardner B.H., Munroe K.J., Leombruno D., Recchia J., Kensil C.R., Coughlin R.T. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. J. Immunol. 148:1992;2357-2362.
47. Dukema R., van der Meide P.H., Dubbeld M., Caspers M., Wubben J., Schellekens H. Cloning, expression, and purification of rat IFN-γ Meth. Enzymol. 19:1986;453-464.